Sugi Predict

Sugi Predict / Compounds / SCHEMBL3016072

SCHEMBL3016072

SCHEMBL3016072

O=S(=O)(c1ccc(Br)cc1Cl)N1CCN(c2nc(Cc3ccc(Cl)c(F)c3)cs2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ KMT2A Q03164 4/20 0.37
▸ MEN1 O00255 3/20 0.37
▸ MAPT P10636 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ PKM P14618 1/20 0.35
▸ HSD11B1 P28845 2/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ MAPK1 P28482 2/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ RIN1 Q13671 1/20 0.34
▸ FPR2 P25090 2/20 0.34
▸ PROKR1 Q8TCW9 2/20 0.34
▸ TRPV4 Q9HBA0 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ DNM1L O00429 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017827 0.94 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL3003595 0.93 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL3016449 0.92 LMNA (0.37) ALDH1A1SMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL3023917 0.91 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL3007155 0.91 TRPV4 (0.43) ALDH1A1SMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL3002727 0.89 SMN1; SMN2 (0.41) ALDH1A1SMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL3019261 0.89 SMN1; SMN2 (0.48) ALDH1A1SMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL3008531 0.89 TRPV4 (0.40) ALDH1A1SMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL3006711 0.88 GAA (0.47) ALDH1A1SMN1; SMN2KMT2AMEN1MAPT
SCHEMBL3012841 0.88 TRPV4 (0.40) ALDH1A1SMN1; SMN2L3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 — — EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 — — US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 — — US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 — — EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.